Linagliptin/Fimasartan Potassium Trihydrate

利格列汀/非马沙坦钾三水合物

Report date: 2024/06/30 20:00:06

Base Information

Drug NameLinagliptin/Fimasartan Potassium Trihydrate
Drug Alias Name利格列汀+非马沙坦钾Fimasartan+Linagliptin利格列汀/非马沙坦钾Linagliptin+Fimasartan非马沙坦钾+利格列汀 +[7] 
ClassificationSmall molecules
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonistsDipeptidyl peptidase IV inhibitors
TargetsAngiotensin II Receptor Type 1Dipeptidyl peptidase IV
Therapy Area/IndicationsDiabetes MellitusHypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsYes LinagliptinFimasartan Potassium Trihydrate
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBoryung Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBoryung Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsDiabetes MellitusHypertension

Other Information

ATC CodeN/A
Related LinksN/A